Canton Strategic Holdings, Inc.
Close on Oct 19, 2026
- Market cap
- $366.50M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 14, 2026 | During market hours | $1.50M | $-0.08 | – |
Press releases
Announcements Canton Strategic filed with the SEC
Strategic Holdings, Inc. Releases Second Quarter 2026 Financial and Operational Results
Results of operations · EX-99.1 to Form 8-K
PRO FORMA CONSOLIDATED CONDENSED FINANCIAL INFORMATION
Material agreement · Acquisition or disposition completed · Other events · EX-99.1 to Form 8-K
Strategic Holdings, Inc. Announces Sale of Gravitas Life Sciences, LLC.
Material agreement · Acquisition or disposition completed · Other events · EX-99.2 to Form 8-K
Strategic Holdings, Inc. Announces Authorization of Share Repurchase Program
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Strategic Holdings Reports Full Year 2025 Financial and Operational Results
Other events · EX-99.1 to Form 8-K
Strategic Holdings, Inc. Chairman and CEO Mark Wendland Elected to Canton Foundation Board
Other events · EX-99.1 to Form 8-K
Inc. Announces Corporate Rebrand to Canton Strategic Holdings, Inc., Marking Milestone in Canton Network Digital Asset Treasury Strategy
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating Officer
Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Elects Jill Sommers and William Wiley to Board of Directors
Shareholder vote results · Other events · EX-99.1 to Form 8-K
Announces Expanded Role as Super Validator on Canton Network
Other events · EX-99.1 to Form 8-K
Inc. Announces Closing of $55 Million Underwritten Registered Direct Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Inc. Announces Pricing of $55 Million Underwritten Registered Offering
Other events · EX-99.1 to Form 8-K
Inc. Appoints Jacob Asbury as Chief Financial Officer to Advance Canton Coin Treasury Strategy
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Closes $545 Million Private Placement to Establish Canton Coin Treasury Strategy
Material agreement · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Inc. Announces Private Placement of Approximately $540 Million Led by DRW and Liberty City Ventures to Establish Canton Coin Treasury
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Prepaid expenses and other current assets
Other events · EX-99.1 to Form 8-K
Davis, Visionary Philanthropist and Founder of Race to Erase MS and Cure Addiction Now Appointed to the Tharimmune Board of Directors
Executive or director change · Other events · EX-99.1 to Form 8-K
Tharimmune Announces Pricing of $1.74 Million
Material agreement · Other events · EX-99.1 to Form 8-K
Announces $2.02 Million Private Placement to Advance Development Programs
Material agreement · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Signs Nonbinding Letter of Intent to Merge with Intract Pharma to Create Transformative Oral Biologic Therapeutics Company
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Acquires Global License and Partners with Intract Pharma to Develop an Oral Formulation of Infliximab
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
Announces $2.08 Million Private Placement
Material agreement · Other events · EX-99.1 to Form 8-K
Announces 1-for-15 Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (PBC)
Other events · EX-99.1 to Form 8-K
Tharimmune Announces 1-for-25 Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Executes Exclusive Global Licensing Agreement for Innovative Clinical Stage Asset for Chronic Pruritis
Material agreement · Other events · EX-99.1 to Form 8-K
BioPharma progressing towards acquiring clinical stage asset and announces corporate name change to Tharimmune, Inc.
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
BioPharma Strengthens its Board of Directors with Appointment of Kelly Anderson
Executive or director change · Other events · EX-99.1 to Form 8-K
BioPharma Announces Proposed Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
BioPharma Announces Pricing of Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K